Viking Therapeutics (VKTX) Posts Q2 Loss of $1.07/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 13, 2015 7:44 AM EDTPhase 2 Clinical Studies to Begin in Acute Hip Fracture and Hypercholesterolemia/Fatty Liver Disease
Completes $22.3 Million IPO
SAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for the second quarter of 2015 and provided an update on its clinical pipeline and other corporate developments.
Highlights From, and Subsequent to, the Three Months Ended June 30, 2015
"We made... More
